Efficacy and Safety of Sulcardine Sulfate Tablets in Patients With Premature Ventricular Contractions

A Single-dose, Open Labeled, Multicenter Phase IIa Clinical Study on the Efficacy and Safety of Sulcardine Sulfate Tablets in Patients With Premature Ventricular Contractions

Arrhythmia is a common disease that may be caused by various cardiovascular diseases. According to statistics, 500,000 people die of severe arrhythmia every year in China, In the United States, approximately 540,000 patients die each year.This study will evaluate the effectiveness safety of sulcardine sulfate tablets in the patients with premature ventricular contractions (and non-sustained VT).

Study Overview

• Status: Unknown
• Conditions: Premature Ventricular Contraction

Detailed Description

Arrhythmia is a common disease that may be caused by various cardiovascular diseases. The incident rate of various types of arrhythmias may be as high as 86-100% in patients who experience acute myocardial infarction within 10 days. Serious arrhythmias can endanger lives instantly. According to statistics, 500,000 people die of severe arrhythmia every year in China, which constitutes approximately 50% of the death rate for cardiovascular diseases. In the United States, among 1,500,000 myocardial infarction patients, approximately 540,000 patients die each year, which is mainly caused by ventricular fibrillation (VF) and sudden cardiac death (SCD).

Initially at least 24 subjects who meet the inclusion criteria and do not meet the exclusion criteria will be enrolled into either of two dose levels under a 3:1 randomization (active:placebo) take sulcardine sulfate tablets.Dose levels may be dropped, an intermediate dose level added as needed to deemed appropriate following review of safety and tolerability data at the prior dose level(200mg,400mg). A safety review committee will review data from all enrolled subjects at the simultaneous completion of Dosing Cohort 1 and 2 prior to advancement to the final dose level (800mg BID).

• Study Type: Observational
• Enrollment (Anticipated): 36

Contacts and Locations

Study Locations

• China
  • Beijing
    • Beijing, Beijing, China, 100020
      • Recruiting
      • Beijing chao-yang hosipital
      • Contact: Gao M Ming, doctor; Phone Number: 8610-010-85231936; Email: gaomingming168@vip.sina.com
      • Contact: Liu J Mei, doctor; Phone Number: 8610-010-85231936; Email: liujiamei2006@163.com
      • Principal Investigator: Yang Xin Chun, doctor
    • Beijing, Beijing, China, 100044
      • Recruiting
      • Peking university people's hosipital
      • Contact: zhang Ping, doctor; Phone Number: 0086-010-88325264; Email: zhp1024@263.net
      • Contact: Li Chun, doctor; Phone Number: 0086-010-88325264; Email: yxh9956@vip.sina.com
      • Principal Investigator: Guo Ji Hong, doctor

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

18-70 year-old patients with premature ventricular contractions or non-sustained ventricular tachycardia (VT)

Description

Inclusion Criteria:

1. Age 18-70 years old, body weight 45-80kg, and no sex preference.
2. Frequent premature ventricular contraction, the total number of premature ventricular beats indicated by Holter monitor greater than 3600 over 24 hours, with or without a short array of non-sustained ventricular tachycardia (more than 3, but fewer than 10 consecutive ventricular beats).
3. Negative pregnancy test result within 24 hours before the first dose for women of childbearing age. Females subjects of child bearing age must be on effective birth control (IUD or compliant use of oral contraceptive), have been surgically sterilized or abstain from sexual intercourse through the active dosing period and for the first 10 days after dosing.
4. Voluntary participation in the study and the ability to complete the screening and trial procedures, and to remain in the clinical study site throughout dosing period in accordance with the protocol.
5. Understand and voluntarily sign a written informed consent document.

Exclusion Criteria:

1. History of Stage III-IV congestive heart failure.
2. Ejection fraction <35% predicted
3. Polymorphic ventricular tachycardia, sustained ventricular tachycardia.
4. Congenital or acquired long QT syndrome, Torsade de Pointes, or an uncorrected QT-interval of >480 ms; QRS>120 ms.
5. Unstable angina, active myocarditis, rheumatic fever, or bacterial endocarditis, elevated Troponin T on work-up.
6. Sinus node dysfunction, atrioventricular block above first degree not controlled by pacemaker.
7. Complete left or right bundle branch block, or intraventricular block.
8. Hypotension, sitting resting blood pressure below 90/55mmHg.
9. Hypertension as defined by SBP> 160mmHg and/or DBP > 95mmHg
10. Sinus bradycardia (average heart rate lower than 50 beats/min).
11. Liver (liver function tests or bilirubin (direct or indirect) >2XULN, history of cirrhosis or chronic active hepatitis.
12. Kidney dysfunction (plasma creatinine>1.8 and creatinine clearance calculation <30 as determined by Cockroft-Gault calculation) or electrolyte or acid-base balance disorders.
13. Taking digitalis, tricyclic antidepressants, β blockers, or calcium channel blockers within 5 half-lives for a given agent.
14. Thyroid dysfunction.
15. Serious respiratory diseases, Wolff-Parkinson-White syndrome; chronic obstructive pulmonary disease, asthma requiring medication
16. Cyanotic or other uncorrected significant congenital heart disease.
17. History of allergy to sulfonamides.
18. Taking other anti-arrhythmic drugs or medications that affect cardiac electrophysiology, or stop taking the above mentioned medications less than 5 half-life of the drug ago.
19. History of taking amiodarone within 1 years.
20. Severe neurosis, menopausal syndrome, chest pain caused by cervical spondylosis.
21. Diseases of the hematopoietic system, or mental illness.
22. Current evidence of alcohol abuse or history of illegal drug abuse.
23. Women of childbearing potential who are pregnant or nursing, or women of childbearing age who are not on effective birth control (IUD or compliant use of oral contraceptives and who have a positive urine pregnancy test prior to study.
24. Participation in a clinical trial of other drugs within 3 months.
25. Those considered not suitable to be selected by the investigators.

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Control
• Time Perspectives: Cross-Sectional

Collaborators and Investigators

• Sponsor: Jiangsu Furui Pharmaceuticals Co., Ltd

Study record dates

Study Major Dates

• Study Start: November 1, 2010

Study Registration Dates

• First Submitted: November 4, 2010
• First Submitted That Met QC Criteria: November 4, 2010
• First Posted (Estimate): November 5, 2010

Study Record Updates

• Last Update Posted (Estimate): November 5, 2010
• Last Update Submitted That Met QC Criteria: November 4, 2010
• Last Verified: November 1, 2010

More Information

Terms related to this study

• Keywords: Premature ventricular contraction; Frequent premature ventricular contraction, with or without a short array of non-sustained ventricular tachycardia
• Additional Relevant MeSH Terms: Pathologic Processes; Heart Diseases; Cardiovascular Diseases; Arrhythmias, Cardiac; Cardiac Conduction System Disease; Pregnancy Complications; Obstetric Labor Complications; Obstetric Labor, Premature; Cardiac Complexes, Premature; Premature Birth; Ventricular Premature Complexes
• Other Study ID Numbers: TG0823SUL